6 курс / Кардиология / Коронарное_стентирование_и_стенты
.pdf178.Chisari A., Pistritto A.M., Piccolo R. et al. The Ultimaster BiodegradablePolymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence // Int. J. MolSci. 2016 [Электронный ресурс]doi: 10.3390/ijms17091490.
179.Xu B., Dou K.F., Han Y.L. et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results // Chin. Med. J.
(Engl.). Vol. 011. N124(6). P. 811-816.
180.Прохорихин А.А., Байструков В.И., Гражданкин И.О. и др. Простое слепое проспективное рандомизированное мультицентровое исследование эффективности и безопасности сиролимус-доставляющего коронарного стента «КАЛИПСО» и эверолимус-доставляющего коронарного стента XiencePrime: результаты исследования «ПАТРИОТ» // Патология кровообращения и кардиохирургия. 2017. № 21(3). С. 76-
85.http://dx.doi.org/ 10.21688/1681-3472-2017-3-76-85
181.Кудряшов А.Н., Требушат Д.В., Верин В.В. Современное поколение стентов с лекарственным покрытием: фокус на сиролимус-покрытый стент «Калипсо» // Патология кровообращения и кардиохирургия. 2017. № 21(1).
С. 37-43.
182.Kim C.H., Han J.K., Yang H.M. Study protocol for arandomised controlledtrial: harmonisingoptimal strategy for treatment of coronary arterystenosis - coronary intervention with next-generationdrug-eluting stent platform sand abbreviated dual antiplatelet therapy (HO ST-IDEA) trial // BMJOpen. 2017[Электронныйресурс] doi: 10.1136/bmjopen-2017-016617.
183.Derimay F., Souteyrand G., Motreff P. et al. Influence of platform design of six different drug-eluting stents in provisional coronary bifurcation stenting by rePOT sequence: a comparative bench analysis // EuroIntervention. 2017. Vol. 13, N 13(9). P. 1092-1095.
184.Производитель Boston Scientific. [Электронный ресурс] URL:
http: www.bos-tonscientific.com.en-US.products.stents-coronary.ion-stent- system.html.
185.Puri R., Otaegui I., Sabaté M. et al. Threeand 6-month optical coherence tomo-graphic surveillance following percutaneous coronary intervention with the An-giolite® drug-eluting stent: The ANCHOR study // Catheter. Cardiovasc. Interv. 2018. Vol. 15. N91(3). P. 435-443.
186.Gil R.J., Vassilev D., Bil J. et al. Dedicated Bifurcation Drug-eluting Stent BiOSS® - A Novel Device for Coronary Bifurcation Treatment // Interv. Cardiol.
Медицинские книги
@medknigi
2013. Vol. 8(1). P. 19-22.
187.Производитель Rontismedical. [Электронный ресурс]
URL: http://rontismed-ical.com/phoenix-pico.
188.Waksman R., Piegari G.N., Kabour A. et al. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month an-giographic and clinical follow-up of the prospective, multicenter BioFreedom USA
clinical trial // Cardiovasc. Revasc. Med. 2017. Vol. 18(7). P. 475-481.
189.Ellert J., Antonsen L., Jensen L.O. et al. Early restenose in a polymer-free Biolimus A9-coated stent (BioFreedom): A case report based on optical coherence tomography // Cardiovasc. Revasc. Med. 2017. Vol. 18(3). P. 207-211.
190.Производитель ComedBV. [Электронный ресурс] URL:
http: comedbv.com. product.miranda-druf-eluting-coronary-stent.
191.Производитель Eurocor. http://www.eurocor.de/products/e_magic_plus/
192.Производитель ACCURAMEDIZINTECHNIK. [Электронный ресурс]URL: http: www.accuramed.de.cardiology.decent-s.index.html.
193.Hiremath M.S. Evaluation and efficacy of long length Pronova XR Bioabsorbable Polymer stent in the treatment of long coronary lesions // Indian. Heart J. 2017.
Vol. 69(6). P. 690-694.
194.Deshpande N.V., Admane P., Deshpande M. et al. A prospective study evaluating efficacy of polymer free Pronova XR stent in treatment of denovo coronary artery stenosis // Indian. Heart. J. 2014. Vol. 66(1). P. 11-15.
195.Legutko J., Zasada W., Kałuża G.L. et al. A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study) // Indian Heart J. 2013. Vol. 65(4). P. 388-394.
196.Takimura C.K., Galon M.Z., Gutierrez P.S. et al.A new polymer-free drugeluting stent with nanocarriers eluting sirolimus from stent-plus-balloon compared with bare-metal stent and with biolimus A9 eluting stent in porcine coronary arteries //
Cardiovasc. Diagn. Ther. 2015. Vol. 5(2). P. 113-121.
197. Babic Z., Gabric I.D., Pintaric H. Successful primary percutaneous coronary intervention in the first trimester of pregnancy // Catheter. Cardiovasc. Interv. 2011. Vol. 1, N 77(4). P. 522-525.
Медицинские книги
@medknigi
198. Briguori C., Visconti G., Donahue M. et al. Performance of the XLIMUS Siroli- mus-Eluting Coronary Stent in Very Complex Lesions // J. Interv. Cardiol. 2016.
Vol. 29(6). P. 559-568.
199. Briguori C., Visconti G., Focaccio A. et al. Performance of the XLIMUS siroli- mus-eluting coronary stent in very complex lesions // Minerva Cardioangiol. 2014.
Vol. 62(1). P. 1-8.
200.Ellis S.G. Fantom Bioresorbable Scaffold: Verse, But Not Yet Chorus (An Incomplete Composition) // JACC Cardiovasc. Interv. 2017. Vol. 25, N10(18). P. 1839-1840.
201.Abizaid A., Carrié D., Frey N. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold:
The FANTOM II Study // JACC Cardiovasc. Interv. 2017. Vol. 25, N 10(18). P. 18321838.
202.Ormiston J., Serruys P.W. Bioabsorbable coronary stents // JACC. 2010. Vol. 56 (10). P. 255-260.
203.Зверев Д.A. Биoaбcopбиpyeмыe коронарные cτeнτы ⁄/ Биомедицинская инженерия. 2001. № 3(15). С. 2-6.
204.Gard S., Serruys P.W. Coronary stents. Looking forward // JACC. 2010. Vol. 56 (10). P. 60-66.
205.Электронный ресурс http://advancedbifurcation.com/absplatform/
206.Wu Y., Shen L., Ge L. et al. Six-month outcomes of the XINSORB bioresorba- blesirolimus-eluting scaffold in treating single de novo lesions in human coronary artery // Catheter. Cardiovasc. Interv. 2016. Vol. 87(1). P. 630-637.
207.Shen L., Wu Y., Ge L. et al. A head to head comparison of XINSORB bioresorb-ablesirolimus-eluting scaffold versus metallic sirolimus-eluting stent:
180days follow-up in a porcine model // Int. J. Cardiovasc. Imaging. 2017. Vol. 33(10). P. 1473-1481.
208.Mishra S. A fresh look at bioresorbable scaffold technology: Intuition pumps // Indian. Heart J. 2017. Vol. 69(1). P. 107-111.
209.Kazuyuki Yahagi, MD; Yi Yang, MD; Sho Torii, MD et al. Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up // Journal of the American Heart Association. 2017. [Электронный ресурс] doi: 10.1161/
JAHA.117.005693.
Медицинские книги
@medknigi
210. Vahl T.P., Gasior P., Gongora C.A. et al. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries // EuroIntervention. 2016. Vol. 20, N 12(12). P. 1510-1518.
Медицинские книги
@medknigi